Genfit S.A. (GNFT.PA)
EUR 3.5
(2.04%)
EUR 3.5
(2.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -28.05 Million EUR | -102.24% |
| 2022 | -23.6 Million EUR | -121.71% |
| 2021 | 34.9 Million EUR | 217.77% |
| 2020 | -91.13 Million EUR | -42.96% |
| 2019 | -51.02 Million EUR | 29.6% |
| 2018 | -68.07 Million EUR | -22.83% |
| 2017 | -55.75 Million EUR | -66.42% |
| 2016 | -33.52 Million EUR | -97.84% |
| 2015 | -17.34 Million EUR | 0.2% |
| 2014 | -16.97 Million EUR | -71.79% |
| 2013 | -9.95 Million EUR | -42.76% |
| 2012 | -6.77 Million EUR | -2.04% |
| 2011 | -6.63 Million EUR | -1.66% |
| 2010 | -6.53 Million EUR | -26.7% |
| 2009 | -5.09 Million EUR | -46.83% |
| 2008 | -3.4 Million EUR | 14.25% |
| 2007 | -4.06 Million EUR | -3595.56% |
| 2006 | 930.3 Thousand EUR | -95.5% |
| 2005 | 2.6 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 32 Million EUR | 0.0% |
| 2023 Q3 | 2.81 Million EUR | 112.3% |
| 2023 FY | - EUR | -102.24% |
| 2023 Q2 | -22.9 Million EUR | 0.0% |
| 2023 Q4 | -15.51 Million EUR | -650.39% |
| 2022 Q2 | -16.55 Million EUR | 0.0% |
| 2022 Q3 | 5.31 Million EUR | 132.08% |
| 2022 FY | - EUR | -121.71% |
| 2022 Q4 | 6.09 Million EUR | 14.78% |
| 2021 Q2 | -29.96 Million EUR | 0.0% |
| 2021 Q4 | 59.91 Million EUR | 0.0% |
| 2021 FY | - EUR | 217.77% |
| 2020 Q4 | -29.05 Million EUR | 0.0% |
| 2020 FY | - EUR | -42.96% |
| 2020 Q2 | -52.71 Million EUR | 0.0% |
| 2019 Q4 | -8.17 Million EUR | 0.0% |
| 2019 FY | - EUR | 29.6% |
| 2019 Q2 | -48.03 Million EUR | -276.57% |
| 2019 Q1 | -12.75 Million EUR | 65.82% |
| 2018 FY | - EUR | -22.83% |
| 2018 Q4 | -37.31 Million EUR | 0.0% |
| 2018 Q2 | -30.72 Million EUR | -83.2% |
| 2018 Q1 | -16.77 Million EUR | 50.04% |
| 2017 Q4 | -33.57 Million EUR | 0.0% |
| 2017 FY | - EUR | -66.42% |
| 2017 Q1 | -13.85 Million EUR | 33.9% |
| 2017 Q2 | -22 Million EUR | -58.81% |
| 2016 FY | - EUR | -97.84% |
| 2016 Q2 | -12.56 Million EUR | -53.72% |
| 2016 Q1 | -8.17 Million EUR | 4.31% |
| 2016 Q4 | -20.95 Million EUR | 0.0% |
| 2015 FY | - EUR | 0.2% |
| 2015 Q3 | -4.2 Million EUR | 52.27% |
| 2015 Q2 | -8.8 Million EUR | -109.52% |
| 2015 Q1 | -4.2 Million EUR | 46.96% |
| 2015 Q4 | -8.54 Million EUR | -103.36% |
| 2014 FY | - EUR | -71.79% |
| 2014 Q1 | -4.15 Million EUR | 13.19% |
| 2014 Q3 | -4.15 Million EUR | 54.06% |
| 2014 Q2 | -9.05 Million EUR | -117.65% |
| 2014 Q4 | -7.92 Million EUR | -90.46% |
| 2013 Q3 | -2.44 Million EUR | 52.69% |
| 2013 FY | - EUR | -42.76% |
| 2013 Q4 | -4.79 Million EUR | -96.27% |
| 2013 Q2 | -5.16 Million EUR | -111.38% |
| 2013 Q1 | -2.44 Million EUR | 0.0% |
| 2012 Q1 | -1.73 Million EUR | 0.0% |
| 2012 Q4 | -2.44 Million EUR | -40.82% |
| 2012 FY | - EUR | -2.04% |
| 2012 Q2 | -1.73 Million EUR | 0.0% |
| 2012 Q3 | -1.73 Million EUR | 0.0% |
| 2011 Q3 | -1.65 Million EUR | 0.0% |
| 2011 Q1 | -1.65 Million EUR | 0.0% |
| 2011 Q2 | -1.65 Million EUR | 0.0% |
| 2011 Q4 | -1.73 Million EUR | -4.44% |
| 2011 FY | - EUR | -1.66% |
| 2010 Q1 | -1.64 Million EUR | 0.0% |
| 2010 Q2 | -1.64 Million EUR | 0.0% |
| 2010 Q3 | -1.64 Million EUR | 0.0% |
| 2010 Q4 | -1.65 Million EUR | -0.72% |
| 2010 FY | - EUR | -26.7% |
| 2009 FY | - EUR | -46.83% |
| 2009 Q4 | -1.64 Million EUR | -28.08% |
| 2009 Q3 | -1.28 Million EUR | 0.0% |
| 2009 Q2 | -1.28 Million EUR | 0.0% |
| 2009 Q1 | -1.28 Million EUR | 0.0% |
| 2008 Q2 | -876.3 Thousand EUR | 0.0% |
| 2008 Q4 | -1.28 Million EUR | -46.83% |
| 2008 Q3 | -876.3 Thousand EUR | 0.0% |
| 2008 Q1 | -876.3 Thousand EUR | 0.0% |
| 2008 FY | - EUR | 14.25% |
| 2007 Q2 | -1.01 Million EUR | 0.0% |
| 2007 Q3 | -1.01 Million EUR | 0.0% |
| 2007 Q4 | -876.3 Thousand EUR | 13.34% |
| 2007 FY | - EUR | -3595.56% |
| 2007 Q1 | -1.01 Million EUR | 0.0% |
| 2006 Q2 | 152.35 Thousand EUR | 0.0% |
| 2006 Q4 | -1.01 Million EUR | -763.75% |
| 2006 FY | - EUR | -95.5% |
| 2006 Q1 | 152.35 Thousand EUR | 0.0% |
| 2006 Q3 | 152.35 Thousand EUR | 0.0% |
| 2005 Q3 | 825.75 Thousand EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2005 Q2 | 825.75 Thousand EUR | 0.0% |
| 2005 Q1 | 825.75 Thousand EUR | 0.0% |
| 2005 Q4 | 152.35 Thousand EUR | -81.55% |
| 2004 Q4 | 825.75 Thousand EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -752.614% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 78.942% |
| Adocia SA | -22.73 Million EUR | -23.399% |
| Aelis Farma SA | -6.34 Million EUR | -341.957% |
| Biophytis S.A. | -13.8 Million EUR | -103.209% |
| Advicenne S.A. | -6.24 Million EUR | -349.247% |
| genOway Société anonyme | 6.35 Million EUR | 541.696% |
| IntegraGen SA | -52.5 Thousand EUR | -53327.423% |
| Medesis Pharma S.A. | -3.84 Million EUR | -629.567% |
| Neovacs S.A. | -8.44 Million EUR | -231.982% |
| NFL Biosciences SA | -4.04 Million EUR | -592.737% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 38775.031% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -876.203% |
| Sensorion SA | -22.31 Million EUR | -25.711% |
| Theranexus Société Anonyme | -7.38 Million EUR | -279.723% |
| TME Pharma N.V. | -5.07 Million EUR | -453.056% |
| Valbiotis SA | -6.95 Million EUR | -303.321% |
| TheraVet SA | -517.33 Thousand EUR | -5322.201% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -48.292% |
| argenx SE | -199.5 Million EUR | 85.94% |
| BioSenic S.A. | -6.79 Million EUR | -312.758% |
| Celyad Oncology SA | -7.76 Million EUR | -261.342% |
| DBV Technologies S.A. | -79.53 Million EUR | 64.729% |
| Galapagos NV | 51.03 Million EUR | 154.962% |
| GeNeuro SA | -14.31 Million EUR | -95.918% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -87.256% |
| Innate Pharma S.A. | -7.57 Million EUR | -270.164% |
| Inventiva S.A. | -101.84 Million EUR | 72.458% |
| MaaT Pharma SA | -19.74 Million EUR | -42.102% |
| MedinCell S.A. | -20.04 Million EUR | -39.933% |
| Nanobiotix S.A. | -34.01 Million EUR | 17.543% |
| Onward Medical N.V. | -35.23 Million EUR | 20.387% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -532.726% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | -20.566% |
| Oxurion NV | -16.72 Million EUR | -67.679% |
| Pharming Group N.V. | 4.98 Million EUR | 663.164% |
| Poxel S.A. | -12.17 Million EUR | -130.323% |
| GenSight Biologics S.A. | -21.73 Million EUR | -29.089% |
| Transgene SA | -27.02 Million EUR | -3.8% |
| Financière de Tubize SA | 184.57 Thousand EUR | 15297.946% |
| UCB SA | 1.26 Billion EUR | 102.21% |
| Valneva SE | -64.51 Million EUR | 56.522% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 1.065% |